Thomas Steger-Hartmann
Bayer
67 Papers
553 Citations
Thomas Steger-Hartmann is an academic researcher from Bayer. The author has contributed to research in topics: Medicine & Computer science. The author has an hindex of 25, co-authored 56 publications. Previous affiliations of Thomas Steger-Hartmann include Schering AG & Bayer HealthCare Pharmaceuticals.
Chat about Author
Papers
Benchmark data set for in silico prediction of Ames mutagenicity.
Katja Hansen,Sebastian Mika,Timon Schroeter,Andreas Sutter,Antonius Ter Laak,Thomas Steger-Hartmann,Nikolaus Heinrich,Klaus-Robert Müller +7 more
TL;DR: A new unique public Ames mutagenicity data set comprising about 6500 nonconfidential compounds together with their biological activity is described and three commercial tools and an off-the-shelf Bayesian machine learner in Pipeline Pilot are compared.
Effects of synthetic gestagens on fish reproduction.
Jana Zeilinger,Thomas Steger-Hartmann,Edmund Maser,Stephan Goller,Richardus Vonk,Reinhard Länge +5 more
TL;DR: The effects of two progestins currently marketed in contraceptive formulations, levonorgestrel (LNG) and drospirenone (DRSP), were investigated in adult fathead minnows following an Organization for Economic Cooperation and Development 21-d fish reproduction screening assay draft protocol with additional end points.
291
Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.
Uwe Marx,Tommy B. Andersson,Anthony Bahinski,Mario Beilmann,Sonja Beken,Flemming R. Cassee,Murat Cirit,Mardas Daneshian,Susan Fitzpatrick,Olivier Frey,Claudia Gaertner,Christoph Giese,Linda G. Griffith,Thomas Hartung,Minne B. Heringa,Julia Hoeng,Wim H. de Jong,Hajime Kojima,Jochen Kuehnl,Marcel Leist,Andreas Luch,Ilka Maschmeyer,D. A. Sakharov,Adriënne J.A.M. Sips,Thomas Steger-Hartmann,Danilo A. Tagle,Alexander G. Tonevitsky,Tewes Tralau,Sergej Tsyb,Anja van de Stolpe,Rob J. Vandebriel,Paul Vulto,Jufeng Wang,Joachim Wiest,Marleen Rodenburg,Adrian Roth +35 more
TL;DR: The status quo of microphysiological systems available today against industry needs is reviewed, and the broad variety of approaches with fit-for-purpose potential in the drug development cycle are assessed, and feasibility solutions to reach the next levels of human biology in vitro are proposed.
Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage
TL;DR: The biodegradability of the widely used anti-tumour agent ifosfamide was assessed with the modified Zahn-Wellens test and a test simulating biological sewage treatment, indicating that no adsorption, biodegradation or other elimination of IF took place to any noticeable extent.
245
Biological Degradation of Cyclophosphamide and Its Occurrence in Sewage Water
TL;DR: The mutagenic and cancerogenic antineoplastic agent cyclophosphamide (CP) is released into sewage water by cancer patient excretion and in an attempt to assess the contribution of CP to the genotoxicity detected in hospital waste water in a recent study the effects of CP in the umuC test were investigated.
207